Mounjaro Cost and Insurance Coverage in 2026: What You Need to Know

Mounjaro is expensive without insurance coverage, and the coverage landscape remains complicated. Here is a straightforward breakdown of what the medication costs, how insurance typically handles it, and what options exist for reducing your out-of-pocket expense.

Cost is the single biggest barrier to accessing Mounjaro for most patients. The list price is high, insurance coverage is inconsistent, and the savings programs have restrictions that exclude large portions of the patient population. If you are trying to figure out what you will actually pay, this guide covers the current landscape as of early 2026.

The List Price

Eli Lilly's wholesale acquisition cost (WAC) for Mounjaro is approximately $1,023 per month for all dose levels. This is the list price before any discounts, rebates, or insurance negotiations. It is the same whether you are on the 2.5 mg starting dose or the 15 mg maximum dose.

Retail pharmacy cash prices, which reflect what you would pay without insurance at a retail pharmacy, range from roughly $950 to $1,100 per month depending on the pharmacy and location. Discount platforms like GoodRx, RxSaver, and others may offer slightly lower prices, but the savings for brand-name drugs with no generic equivalent are typically modest.

Commercial Insurance Coverage

For patients with employer-sponsored or individually purchased commercial health insurance, Mounjaro coverage depends heavily on the specific plan's formulary (the list of drugs it covers).

Several factors determine your coverage:

• Formulary tier. Most plans that cover Mounjaro place it on a specialty or non-preferred brand tier, which means higher copays or coinsurance compared to generic medications.
• Prior authorization. Nearly all commercial plans require prior authorization for Mounjaro. Your prescriber must submit documentation demonstrating medical necessity, typically showing that you have a diagnosis of type 2 diabetes and have tried or are ineligible for first-line treatments like metformin.
• Step therapy. Some plans require that you try and fail on other GLP-1 medications (such as Trulicity or Ozempic) before covering Mounjaro. This is called step therapy or fail-first requirements.
• Off-label use. If your prescriber writes Mounjaro for weight loss rather than type 2 diabetes, many commercial plans will deny coverage. Mounjaro is FDA-approved only for type 2 diabetes. Weight management coverage is available through Zepbound (same molecule, different brand), though formulary coverage for Zepbound also varies widely.

Copays for commercially insured patients who have coverage range widely, from $25 (with manufacturer savings card) to $150 to $300 or more per month depending on the plan's cost-sharing structure.

The Eli Lilly Mounjaro Savings Card

Eli Lilly offers a savings card program for commercially insured patients. The current program terms (subject to change) allow eligible patients to pay as little as $25 per monthly prescription for up to 24 months.

Eligibility requirements:

• Must have commercial health insurance (employer-sponsored or individual market)
• Insurance must cover Mounjaro (the savings card reduces your copay, it does not replace insurance coverage)
• Not available for patients covered by Medicare, Medicaid, Tricare, or other government-funded programs
• Not available for cash-paying patients without insurance

The savings card works at the point of sale. You present it alongside your insurance card at the pharmacy. The card covers the difference between your insurance copay and $25, up to a maximum monthly benefit. The maximum benefit amount and program duration are subject to change. Check the official Mounjaro website for current terms.

Medicare and Medicaid

Medicare Part D

Medicare Part D plans can cover Mounjaro for type 2 diabetes, and coverage has been expanding. However, there are important caveats:

• Coverage varies by Part D plan. Not all plans include Mounjaro on their formulary.
• Prior authorization is common.
• The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs (effective 2025) helps limit total costs for Medicare beneficiaries, but the monthly cost may still be significant during the initial coverage phase.
• Medicare patients are not eligible for the manufacturer savings card.

Medicare does not cover medications prescribed specifically for weight loss. Mounjaro would only be covered under a type 2 diabetes diagnosis.

Medicaid

Medicaid coverage for Mounjaro varies by state. Some state Medicaid programs cover it for type 2 diabetes with prior authorization. Others have excluded it from their preferred drug lists in favor of less expensive GLP-1 alternatives. Check your state's Medicaid formulary or contact your Medicaid plan directly.

What to Do If You Are Denied Coverage

Insurance denials for Mounjaro are common, particularly on the first attempt. If your claim is denied, several steps can improve your chances on appeal:

1. Understand the reason for denial. Request a written explanation from your insurer. Common reasons include missing prior authorization, step therapy requirements not met, or the drug not being on formulary.
2. Work with your prescriber on prior authorization. Your doctor's office can submit a prior authorization request with supporting documentation. Include your A1C levels, previous medication history, and clinical justification for why Mounjaro is medically necessary for you specifically.
3. File a formal appeal. You have the right to appeal any coverage denial. The appeal should include a letter from your prescriber, relevant lab results, and citations to clinical evidence (such as the SURPASS trials) supporting the medical necessity of tirzepatide for your condition.
4. Request an external review. If your internal appeal is denied, most states allow you to request an independent external review by a third party. This is often more favorable than internal appeals.
5. Contact Lilly's patient support line. Eli Lilly's Mounjaro support team (1-833-807-MJRO) can sometimes help navigate coverage challenges, including helping with prior authorization paperwork.

Alternatives for Reducing Cost

If insurance coverage is not available or affordable, a few other options exist, though none fully solve the cost problem:

• Patient assistance programs. Eli Lilly offers the Lilly Cares Foundation program for uninsured patients who meet income eligibility criteria. Qualifying patients may receive Mounjaro at no cost. Income limits typically apply.
• Specialty pharmacy programs. Some specialty pharmacies offer slightly lower cash prices or payment plans. Mark Cuban's Cost Plus Drugs and similar direct-to-consumer pharmacy models may offer competitive pricing, though availability of specific brand-name drugs varies.
• Compounded tirzepatide. Some compounding pharmacies have offered tirzepatide at lower prices. However, the FDA has raised safety concerns about compounded versions, and the legal and regulatory status of compounded GLP-1 drugs is evolving. The FDA has periodically updated tirzepatide's shortage status, which directly affects compounding legality. Consult your healthcare provider about the safety of compounded alternatives.

The Broader Cost Question

The high price of Mounjaro and other GLP-1 medications has become a significant policy issue. For context, Eli Lilly reported $4.7 billion in Mounjaro revenue in 2023, its first full year on the market. Analysts project the GLP-1 drug class will exceed $100 billion in global revenue by 2030.

There are legitimate arguments on multiple sides. Developing tirzepatide required years of research and billions in clinical trial investment. Type 2 diabetes and obesity impose enormous costs on the healthcare system, and effective treatments could reduce those costs over time. But a medication that most patients need to take indefinitely and that costs over $12,000 per year at list price is simply inaccessible for many of the people who could benefit from it.

Biosimilar competition will eventually bring prices down, but tirzepatide's patent protection extends into the 2030s. In the meantime, the access question remains unresolved for a large number of patients.